A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Loncastuximab tesirine (Primary) ; Mosunetuzumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 30 May 2025 Planned End Date changed from 22 Apr 2025 to 24 Aug 2025.
- 30 May 2025 Planned primary completion date changed from 22 Apr 2025 to 24 Aug 2025.
- 04 Feb 2025 Planned End Date changed from 28 Dec 2024 to 22 Apr 2025.